Antibody-based therapeutics comprise the bulk of approved biologics – as well as biologics that are in development. Pipeline 2 explores the emerging field of next-generation antibody therapeutics, including Antibody-Drug Conjugates, Bispecific Antibody Therapeutics and engineering antibodies that fight cancer. The weeklong Antibody Therapeutics pipeline reveals R&D strategies, clinical results and efficacy data for these promising molecules.
Engineering Next-Generation Cancer Immunotherapies
Bispecific Antibody Therapeutics